Viridian Therapeutics, Inc.

NASDAQ:VRDN

Biotechnology

Healthcare
$30.12 -0.88%

-$0.15 today

Market cap
$3.42B
Beta
0.90
P/E (TTM)
-4.7
EPS (TTM)
-$3.53
52W Low $13.18High $34.29

Volume 1.49M

Average 2.86M

VRDN Total Equity

Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.

Viridian Therapeutics, Inc.NASDAQ: VRDN

Total Equity · Q2 FY2026 · quarter ended Jun 2026

Total equity rises 28.5% from a year ago

Total equity stood at $662.1M at the end of Q2 FY2026, up 28.5% from a year earlier and up 4.1% from the prior quarter. Over 3 fiscal years it compounded at +22.3% a year.

Context

  • Total equity amounted to 60.3% of total assets at the end of Q2 FY2026, down 28.1 pp from a year earlier.
  • Total equity increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether total equity keeps rising in the next quarterly balance sheet after a +28.5% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$662.1M+4.1% QoQ
Last fiscal yearDec 2025
$722.17M+7.5% YoY
Year agoJun 2025
$515.17M+28.5% since
Total Equity past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+28.5%——
1 year+7.5%——
3-year CAGR+22.3%——
5-year CAGR——
10-year CAGR——

Total Equity history

USD · from the balance sheet

Latest · FY2025
722.17M USD
Year-over-year change
+7.5%
4-year CAGR
+40.1%

Total Equity vs competitors

How VRDN compares with its peers on the latest reported figures

  • VRDN's Jun 2026 total equity of $662.1M is the highest of the 4 companies compared; the peer median is $230.47M.
  • Its year-over-year change of +28.5% is the 2nd highest of 4, against a peer median of +10.7%.
  • Total equity amounts to 60.3% of total assets for VRDN, versus a peer median of 80.0%.
VRDN Competitors Peer median
Total Equity for VRDN and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
VRDNViridian Therapeutics, Inc.Jun 2026$662.1M +28.5%+22.3%60.3%
OCULOcular Therapeutix, Inc.Mar 2026$581.57M +118.7%+164.5%79.4%
EYPTEyePoint Pharmaceuticals, Inc.Mar 2026$230.47M -22.8%+47.0%80.0%
OTLKOutlook Therapeutics, Inc.Mar 2026-$28.99M +10.7%—132.4%
Peer median (excluding VRDN) $230.47M+10.7%+105.7%80.0%

Competitors are the stored peer set for VRDN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents42.3M155.58M102.83M99.59M212.38M
Short-term Investments154.67M268.97M374.54M617.99M662.27M
Net Receivables451K102K102K00
Inventory0(6.62M)000
Other Current Assets100K6.52M9.01M20.88M19.58M
Total Current Assets200.16M424.55M486.48M738.46M894.23M
Property, Plant & Equipment (Net)2.06M2.94M3.34M3.44M3.65M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets1.49M7.61M604K501K1.54M
Total Non-current Assets3.55M10.54M3.95M3.94M5.19M
Total Assets203.71M435.09M490.42M742.4M899.42M
Account Payables2.33M14.23M2.24M2.14M8.68M
Short-term Debt00000
Tax Payables00000
Deferred Revenue289K288K288K288K367K
Other Current Liabilities3.75M4.87M12.75M10.74M19.66M
Total Current Liabilities13.64M33.35M26.64M47.87M70.7M
Long-term Debt04.65M20.21M20.58M49.94M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)1.15M861K573K284K34.24M
Other Non-current Liabilities688K1.17M989K2.02M22.37M
Total Non-current Liabilities2.36M6.68M21.77M22.89M106.56M
Total Liabilities15.99M40.03M48.4M70.76M177.25M
Common Stock239K414K540K810K1.02M
Retained Earnings(358.3M)(488.17M)(725.91M)(995.86M)(1.34B)
Accumulated OCI(157K)(390K)338K(10K)447K
Other Stockholders Equity00000
Minority Interest00000
Total Equity187.72M395.06M442.02M671.64M722.17M
Total Debt1.04M5.26M21.05M21.1M50.69M
Net Debt(41.26M)(150.32M)(81.78M)(78.5M)(161.69M)

Viridian Therapeutics, Inc.

NASDAQ:VRDN

Intrinsic Alpha fair value

Locked

Current Price

$30.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.